Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Umbrella Study to Evaluate the Safety, Tolerability, and Clinical Activity of Investigational Agents for Newly Diagnosed, High-Risk, Early-Stage Triple-Negative Breast Cancer

Next Previous
Search
Trial Profile

A Phase 2, Umbrella Study to Evaluate the Safety, Tolerability, and Clinical Activity of Investigational Agents for Newly Diagnosed, High-Risk, Early-Stage Triple-Negative Breast Cancer

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Boserolimab (Primary) ; Olaparib (Primary) ; Pembrolizumab (Primary) ; Capecitabine; Carboplatin; Cyclophosphamide; Doxorubicin; Epirubicin; Paclitaxel
  • Indications Triple negative breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Merck Sharp & Dohme

Most Recent Events

  • 08 Apr 2025 Planned initiation date changed from 18 Mar 2025 to 26 Mar 2025.
  • 08 Apr 2025 Status changed from not yet recruiting to recruiting.
  • 24 Feb 2025 New trial record

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top